Autoinflammatory & rare systemic diseases
Prescription Claims for Immunomodulator and Antiinflammatory Drugs Among Persons With Ehlers‐Danlos Syndromes
Authors' conclusion
To our knowledge, our study is the first to examine the full range of IMD drug prescription claim trends among persons with EDS.
Study context
- Population
- Persons with Ehlers-Danlos Syndromes (EDS) (ages 5–62 years) and matched controls in US private prescription claims data, 2005–2014; 70% adults, 74% femalematched cohort
- Exposure
- Persons with EDS vs matched control persons
- EDSn = 3,484
- Outcome
- Prevalence of prescription claims for immunomodulator and antiinflammatory (IMD) drugs
Methodological detailsmatched on age, sex, state of residence and earliest claim date, private prescription claims database, 2005-2014, minimum 2-year enrollment
- Matched on age, sex, state of residence and earliest claim date
- Private prescription claims database, 2005-2014
- Minimum 2-year enrollment
Main finding
As reported in the abstract
At least 1 IMD medication prescribed
Each group vs control personsConditional OR, biologic agents (95% CI)
EDS
1.3(0.8–2.0)
- EDS
- odds, 5 of 6 IMD drug classes 1.3 to 4.2 times higher; P < 0.0001
Observational data: associations, not effects.
Further findings
Peripubertal trends
- Peripubertal increases observed for NSAIDs, oral and injectable steroids
Original publication
Prescription Claims for Immunomodulator and Antiinflammatory Drugs Among Persons With Ehlers‐Danlos Syndromes. Arthritis Care Res (Hoboken). Published 20 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →